July 15, 2025

Supplementary Data S3 from Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Research demonstrates mechanism of favorable response to decitabine in TP53-mutated MDS/AML, suggesting reasons for relapse.

MAIN FINDING: Decitabine shows an initial favorable response in patients with TP53-mutated MDS/AML.
KEY EVIDENCE: scRNA-seq data reveals changes in the cellular environment during treatment.
APPROACH: The analysis utilized single-cell RNA sequencing to explore cellular responses in tumors.
SIGNIFICANCE: Understanding these mechanisms can inform future treatments and strategies to prevent relapse.

Ng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark